Zealand Pharma A/S (OTCMKTS:ZLDPF) Now Covered by Cantor Fitzgerald

Investment analysts at Cantor Fitzgerald initiated coverage on shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) in a research report issued on Tuesday, Marketbeat.com reports. The firm set an “overweight” rating on the stock.

Separately, BTIG Research initiated coverage on Zealand Pharma A/S in a report on Thursday, March 7th. They set a “buy” rating on the stock.

Zealand Pharma A/S Price Performance

Zealand Pharma A/S stock opened at $89.65 on Tuesday. The company has a market cap of $4.62 billion, a PE ratio of -49.26 and a beta of 0.67. The company has a fifty day moving average price of $92.44 and a two-hundred day moving average price of $73.19. Zealand Pharma A/S has a 12 month low of $33.42 and a 12 month high of $111.44.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Tuesday, February 27th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.08). The company had revenue of $3.35 million during the quarter, compared to the consensus estimate of $1.97 million. Zealand Pharma A/S had a negative net margin of 213.77% and a negative return on equity of 41.49%. Equities research analysts anticipate that Zealand Pharma A/S will post -2.55 earnings per share for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.